Use access key #2 to skip to page content.
$0.30 0.05 (20.04%)
11/21/2008 3:48 PM

Alfacell Corp (ACEL)

CAPS Rating:
*****

A biopharmaceutical company, primarily engaged in the discovery and development of a new therapeutic class of drugs for the treatment of cancer and other pathological conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

ACEL doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

104 Outperforms
6 Underperforms
 

All-Stars

14 Outperforms
2 Underperforms
 

Members bullish on ACEL are also bullish on:

Members bearish on ACEL are also bearish on:

Ticker Tags

Biotechnology (230), Micro Cap (5043)
Suggest a tag

Alfacell Corp At A Glance

Current Price: $0.30
Last Trade Time: 11/21/2008 3:48 PM
Open: $0.25
Previous Close: $0.25
Daily Range: $0.20 - $0.35
52-Week Range: $0.21 - $2.69
Volume: 62,001
Market Cap: $11.83M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ACEL VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Alfacell Corp (ACEL)

Avatar HAE3 (34.89) Submitted: 3/24/08 2:10 PM

This stock is a real sleeper.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

0

Alfacell Corp (ACEL)

Avatar zzlangerhans (99.48) Submitted: 9/08/07 5:12 PM

I'm definitely running against the grain on this one but I don't think the phase III trial of onconase will be positive. Phase III trials which are the result of data mining from other failed phase III trials do not have a good track record. Since this company is essentially a one trick pony, a nega...More

Replies: 7 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 22 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

1

 (ACEL)

Avatar HAE3 (34.89) Submitted: 3/24/08 2:10 PM : Outperform Start Price: $2.40 ACEL Score: -43.57

This stock is a real sleeper.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACEL)

Avatar Quoinintl (< 20) Submitted: 1/24/08 6:15 PM : Outperform Start Price: $2.60 ACEL Score: -44.02

fda approval...oncanase!!

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (ACEL)

Avatar SAVERITELIQ (< 20) Submitted: 1/24/08 4:45 PM : Outperform Start Price: $2.60 ACEL Score: -44.02

History will be made. New cancer drug finishing successful Phase III trials, hopefully will get FDA approval before end of 2008.


Low float, no gaps to fill, just successfully tested the 200 day moving average.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (ACEL)

Avatar drivdapmony4 (< 20) Submitted: 8/08/07 3:46 PM : Outperform Start Price: $2.34 ACEL Score: -37.92

products pipeline and applications look very strong for future development and partnerships.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACEL)

Avatar Zikar (< 20) Submitted: 7/25/07 12:17 PM : Outperform Start Price: $2.28 ACEL Score: -36.89

Just going with the herd, and I also want to get in before it becomes unratable...

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 22 :   1 2 3 4 5 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links